Effects of SGLT2 inhibitors on post-operative atrial fibrillation in heart surgery
Impact of Sodium-glucose Cotransporter 2 Inhibitors on Post-operative Atrial Fibrillation in Cardiothoracic Surgery
This study is trying to see if taking SGLT2 inhibitors before heart surgery can help reduce the chances of developing post-operative atrial fibrillation in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3280 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Hamad Medical Corporation Industry-sponsored |
| Locations | 2 sites (Doha, DA and 1 other locations) |
| Trial ID | NCT06251453 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the occurrence of post-operative atrial fibrillation (POAF) in patients undergoing various cardiothoracic surgeries, such as coronary artery bypass grafting and valve replacements. It will analyze data from electronic medical records over a six-year period, focusing on the incidence and characteristics of POAF in patients who have used SGLT2 inhibitors for at least one week prior to surgery. The study aims to identify both effectiveness and safety outcomes related to the use of these medications in the surgical context.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old who are undergoing cardiothoracic surgery and have been using SGLT2 inhibitors for at least one week prior to their procedure.
Not a fit: Patients with known atrial fibrillation on anticoagulation or those with chronic kidney disease and a creatinine clearance of less than 25 mL/min may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the protective effects of SGLT2 inhibitors against post-operative atrial fibrillation, potentially improving patient outcomes after heart surgery.
How similar studies have performed: While there is emerging evidence suggesting the benefits of SGLT2 inhibitors in reducing atrial fibrillation, this specific approach in the context of post-operative outcomes is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults \> 18 years undergoing cardiothoracic surgery, including CABG, mechanical valve replacement, bioprosthetic valve replacement, or valve repair. * Use of SGLT2 inhibitors for a minimum of 1 week prior to surgery regardless of DM status. * Resumption of SGLT2 inhibitor after stepping down from the intensive care unit. Exclusion Criteria: * Known AF on anticoagulation. * Chronic kidney disease with CrCl \< 25 mL/min.
Where this trial is running
Doha, DA and 1 other locations
- Alaa Rahal — Doha, Da, Qatar (Recruiting)
- Hamad medical corporation — Doha, Da, Qatar (Recruiting)
Study contacts
- Study coordinator: Alaa Rahhal, Msc
- Email: ARahhal1@hamad.qa
- Phone: 55712353
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.